aTyr Pharma, Inc. (ATYR) Earnings Call Transcripts

23 earnings calls from March 2020 to May 11, 2026

NasdaqCM US Health Care Biotechnology

About aTyr Pharma, Inc.

aTyr Pharma, Inc. (ATYR) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 23 calls on record spanning March 26, 2020 to May 11, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.

Earnings Call History

EarningsCalls.dev has 23 aTyr Pharma, Inc. earnings call transcripts on record, spanning March 26, 2020 to May 11, 2026. Based on this history, aTyr Pharma, Inc. reports quarterly. The most recent call on file is dated May 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker
ATYR
Exchange
NasdaqCM
Country
US
Sector
Health Care
Industry
Biotechnology
Calls on record
23
First call
March 26, 2020
Most recent
May 11, 2026
Reporting cadence
quarterly
Quarter Date
Special Calls May 11, 2026 Read transcript
Special Calls Sep 15, 2025 Read transcript
Q4 FY2024 Mar 13, 2025 Read transcript
Company Conference Presentations Jan 16, 2025 Read transcript
Q4 FY2023 Mar 14, 2024 Read transcript
Special Calls Mar 25, 2023 Read transcript
Q4 FY2022 Mar 9, 2023 Read transcript
Q3 FY2022 Nov 10, 2022 Read transcript
Q2 FY2022 Aug 15, 2022 Read transcript
Q1 FY2022 May 9, 2022 Read transcript
Q4 FY2021 Mar 14, 2022 Read transcript
Q3 FY2021 Nov 10, 2021 Read transcript
Company Conference Presentations Oct 15, 2021 Read transcript
Special Calls Sep 13, 2021 Read transcript
Q2 FY2021 Aug 10, 2021 Read transcript
Special Calls Jun 29, 2021 Read transcript
Q1 FY2021 May 13, 2021 Read transcript
Q4 FY2020 Mar 23, 2021 Read transcript
Special Calls Jan 4, 2021 Read transcript
Q3 FY2020 Nov 12, 2020 Read transcript
Q2 FY2020 Aug 13, 2020 Read transcript
Q1 FY2020 May 12, 2020 Read transcript
Q4 FY2019 Mar 26, 2020 Read transcript